LON:TCF

Theracryf Final Earnings Results & Report

GBX 0.16 0.00 (-2.42%)
As of 11/20/2026 04:34 AM Eastern

Theracryf reported Final earnings on June 3, 2025. The company reported EPS of -GBX 0.36.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Theracryf EPS Results

Actual EPS
-GBX 0.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Theracryf Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Theracryf Final Earnings FAQ

Theracryf (LON:TCF) reported earnings of -GBX 0.36 per share for Final. The report was announced on Tuesday, June 3, 2025.

Theracryf Earnings Headlines

TheraCryf appoints new board member, issues options
Theracryf Plc (TCF.L)
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Theracryf PLC Share Chat (TCF)
See More Theracryf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theracryf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theracryf and other key companies, straight to your email.

About Theracryf

Theracryf (LON:TCF) is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

View Theracryf Profile